← Eichor
Study identifier: NCT05357378 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Safety and Effectiveness of the HIT Reverse HRS

Condition: Degenerative Joint Disease · Osteoarthritis, Hip · Avascular Necrosis of Hip  ·  Sponsor: Hip Innovation Technology

PhaseNA
Planned participants288
Who can joinAll sexes, 50 Years to 75 Years
Healthy volunteersNo

About this study

The purpose of this study is to determine if the use of the HIT Reverse Hip Replacement System is safe and effective in patients undergoing total hip replacement. We will determine whether it is safe and effective by comparing it to the control devices.

This description comes directly from the study's public registry record.

Talk to the study team

George Diamantoni  ·  1-866-832-4471  ·  g.diamantoni@hit-irh.com

Always discuss trial participation with your own doctor first.

Locations (6)

Miami Institute for Joint ReconstructionMiami, Florida, United StatesRecruiting
Advent Health Hospital, CarrollwoodTampa, Florida, United StatesRecruiting
Tampa General Health / Florida Orthopedic InstituteTampa, Florida, United StatesRecruiting
LifeBridge Health Rubin Institute for Advanced OrthopedicsBaltimore, Maryland, United StatesTerminated
Division of Orthopaedic SurgerySomers Point, New Jersey, United StatesRecruiting
JIS OrthopedicsNew Albany, Ohio, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05357378